

Index

a

- aberrant and atypical result. *See* continued method performance verification
- absolute evaluation of intercept 158–159
- acceptable deviation, evaluation of calibration models 159–160
- acceptance criteria 27, 30, 79
 - analytical procedures transfer 353, 355
 - accuracy 132–135
 - detector testing for 31
 - for equivalence testing 358–363
 - precision 95–107
 - procedure performance acceptance criteria (PPAC) 51, 59–64, 69
- acceptance limit 6, 30, 78–79, 83, 84, 125, 288, 291, 319, 320, 367
 - for accuracy 121, 128
 - for observed bias 125
 - joint evaluation of accuracy and precision 136
 - precision 158, 165, 175, 369
 - specification 82, 97, 101, 105, 119, 166, 309, 310
- accuracy 63–64, 177–178, 335
 - and range 119–121, 137
 - – acceptance criteria (ATP requirements) 132–135
 - – drug product 126–127
 - – drug substance 122–126
 - – integration mode accuracy 130–131
 - – and precision joint evaluation 136
 - – response factors 131–132
 - – spiked impurities recovery 129–130
 - quantitative tests 70
 - relationship with precision 64–65
- actuation profile experiments 330–331
- additivity of variances principle 84–85
- analysis of variance (ANOVA) 88, 90–92, 98–99, 101, 117, 264, 277
 - lack-of-fit test 157
- analytical instrument and system qualification (AISQ). *See* under analytical instrument qualification (AIQ)
- analytical instrument qualification (AIQ) 12, 14, 18
 - analytical instrument and system qualification (AISQ) risk-based approaches 20, 23–25
 - data quality and integrity in good manufacturing practice (GMP) 11–12
 - definition 14
 - efficient and economic HPLC performance qualification 36–37
 - – AIQ importance 25–27
 - – continuous PQ general procedures 34–36
 - – control charts 33–34
 - – modular parameters transfer into holistic approach 29–32
 - – OQ/PQ data in comparison with SST data 32–33
 - – revised OQ/PQ parameter list development 27–29
 - importance of 25
 - roles and responsibilities 17–18
 - terminology clarification 19
 - United States Pharmacopeia (USP) General Chapter <1058> 12, 14–20
- analytical procedures transfer 348–349
 - comparative testing 355–371
 - coordination 350, 352
 - experimental studies design and acceptance criteria 353, 355
 - familiarization and training 353

- analytical procedures transfer (*contd.*)
 - regulatory and international guidance 349–350
 - result evaluation and transfer report 355
 - strategy 352–353
- analytical quality by design (AQbD) 217–220, 223–224, 240–241
 - control strategy 239–240
 - design of experiments (DOE) 225–227
 - failure mode effect analysis (FMEA) 227–230
 - illustrative case study 231–234
 - method validation requirements 220–221
 - robustness 221–223
 - statistical analysis for robustness example 234–237
- analytical significance 84
- analytical target profile (ATP) 4–8, 41, 326–334
 - bias and uncertainty in procedure 50–51
 - decision rules 42–43
 - – compliance 43–45
 - – guard bands 48–49
 - – types 47–48
 - derivation 343–345
 - example 56–57
 - feasibility testing 345–346
 - finalizing 346
 - fitness definition 42
 - key performance indicators 51
 - measurement uncertainty 51
 - – estimation 53–55
 - – meaning 51–52
 - – random variability sources 55
 - – reporting 52–53
 - target measurement uncertainty
 - – analysis cost 49–50
 - – calculation 45–47
- analytical transfer team (ATT) 350, 352
- analytical validation
 - analytical life cycle 8–9
 - analytical target profile (ATP) 5–8
 - concepts and process development 1–4
 - three-stage approach to analytical life-cycle validation 4–5
- assay 62
 - accuracy 63–65
 - linearity 67
 - precision 62–65
 - range 67–68
 - specificity 65–67
- automated delivered dose uniformity procedure 333–334
- autosampler 29
 - temperature accuracy 29
- b**
- bias 119, 178
 - and uncertainty 50–51
- c**
- calibration 19, 180–182
 - format optimization 97–99
 - – of impurity determinations 99–101
 - model 121, 162
 - – requirements 146
 - multiple point 146, 159
 - multi-variate 163
 - single-point 88, 119, 121, 151, 152, 158, 161–163, 308, 315
 - universal 122
- chromatographic and functional assays 359–363
- chromatographic system suitability parameters 288–290
 - injection precision 291–293
 - signal-to-noise ratio 290–291
 - system precision for impurities 293
 - test for required detectability 291
- chromatography data system (CDS) 35
- coefficient of correlation 153–154
- coefficient of variation (CV) 62–63, 85–86, 97–98
- combined uncertainty 53
 - calculation 55
- comparative testing
 - direct comparison 367–369
 - – accuracy 370–371
 - – precision 369–370
 - equivalence-based methodology 355–356
 - – acceptance criteria for equivalence testing 358–363
 - – decision procedure 365–367
 - – inter-laboratory study 357–358
 - – principle 356–357
 - – real example 367
 - – statistical analysis 363–364
 - – transfer end-points 358
- compendial/pharmacopeia test procedures implementation 348
 - background 337
 - challenges and need for verification 338–339
 - current approach to verification of procedures 339–340
 - current verification process and lifecycle approach integration 340

- generation and publishing of methods 336–337
- implementation using lifecycle approach 341–346
- performance qualification 346–347
- use of procedures in laboratory for first time 339
- confidence intervals (CIs) 81–84, 150–151, 364
- continued method performance verification 377
 - aberrant data investigation
 - – atypical and aberrant results classification 393–399
 - – laboratory failure investigation 391–393, 405
 - – statistical outlier tests for out-of expectation results 399–405
 - continual improvement 406
 - – control of change 406–409
 - routine monitoring 377–380
 - – control chart application examples to analytical procedures 382–383
 - – control chart establishment 380–382
 - – periodic review 383–385
 - – root cause determination using CuSum analysis 385–390
- continuous knowledge feedback loop 342
- continuous performance qualification (cPQ) 8
 - general procedures 34–36
- control charts 33–34, 378–388
- control strategy 342–343
- critical analytical method variables (CAMVs) 218, 224
- critical method attributes (CMAs) 218, 223–226, 231
- critical method variables (CMVs) 218, 224, 231, 239
- CuSum analysis 385–390

d

- data quality
 - components 14
 - triangle 14
 - – enhanced 22
- decision rules. *See* under analytical target profile (ATP)
- design of experiments (DOE) 209, 212–213, 215, 218, 224–227, 231–234, 239, 245, 258, 286
- design qualification (DQ) 14, 26
- detection limit. *See* under quantitation limit
- detector drift 32

- detector noise 31
- differential scanning calorimetry (DSC) 122
- diode array detection 142–143
- diode array detector (DAD)-UV 199, 200
- Dixon's Q-test 401–403
- DryLab 245–256, 258, 270

e

- empirical procedure 55
- equivalence data analysis methods 363–364
- equivalence tests 124–125, 132, 156
 - for intercept 158
- EURACHEM approach 174, 266
- expanded uncertainty 53
 - calculation 55
- extrapolation 158–159
- extreme studentized deviate (ESD). *See* Grubb's test

f

- failure mode effect analysis (FMEA) 227–230, 331–333
- fish-bone diagram 55, 74, 223, 231, 327, 329, 366
- fit, robustness study 271–276
- flow rate accuracy 29–30
- Food and Drug Administration (FDA) 1, 3, 4
- four Qs model 14–15
- function of mutual information (FUMI) 84

g

- good manufacturing practice (GMP) data quality and integrity 11
 - quality data criteria 11–12
- regulatory rationale for qualified analytical instruments 12
- Graybill–Wang Modified Large Sample (MLS) method 364
- Grubb's test 399, 402
- GUM 46–47

h

- Hampel test 403–405
- heteroscedasticity 160
- high performance liquid chromatography (HPLC) 36–37, 195
 - AIQ importance 25–27
 - calculation method 396
 - calculation table 398
 - continuous PQ general procedures 34–36
 - control charts 33–34, 378–388
 - Dixon's test on example data 403
 - Hampel's method on example data 405
 - injection sequence 396

- high performance liquid chromatography (HPLC) (*contd.*)
 - method qualification for identity, assay, and degradation products case study 308–310
 - – accuracy 318–320
 - – experimental 310
 - – linearity 314–318
 - – precision 320–321
 - – qualification summary 310, 313–314
 - – quantitation limit 321, 323
 - – range 323–324
 - – specificity 314
 - modular parameters transfer into holistic approach 29–32
 - OQ/PQ data in comparison with SST data 32–33
 - peak area data 397
 - revised OQ/PQ parameter list development 27–29
 - risk assessment of change in column manufacturer 408
 - sampling diagram 394
 - standard bracketing scheme 395
- homoscedasticity 148
- HorRat value 69, 93
- Horwitz curve 93
- Horwitz equation 68–69, 93
 - application to concentration values 69–70
- i**
- injection precision. *See* system precision
- injection volume
 - accuracy 27
 - linearity 29
- installation qualification (IQ) 14, 26
- intermediate precision 62–63, 115–116, 179, 203–205, 321
- International Conference on the Harmonisation (ICH) 1–2, 8, 41, 60, 242
- International Society of Pharmaceutical Engineering (ISPE) 349–352
- Ishikawa diagram. *See* fish-bone diagram
- j**
- JMP Pro Statistical software (SAS, version 10.0) 234
- k**
- lack-of-fit tests. *See* statistical linearity tests
- Lambert–Beer law 147
- law of propagation of errors 97
- LC-MS 143–145
- LC-Simulator ACD labs software 203
- least-squares regression. *See* unweighted linear regression
- leverage 150
- limit of detection (LOD) 29
- limit of quantitation (LOQ) 209
- limit tests 69
 - limit of detection (LOD) 69–70
 - precision 70
 - specificity 70
- linearity 145–147, 180, 335
 - assay procedure 67
 - calibration models 162
 - DL/QL determination 167–174
 - of injection volume and detector response 29
 - nonlinear and regression techniques 162–163
 - unweighted linear regression 147–151
 - – graphical evaluation 151–153
 - – intercept evaluation (systematic errors absence) 158–160
 - – numerical regression parameters 153–155
 - – statistical linearity tests 155–158
 - weighted linear regression 160–161
- m**
- Maldener test 85
- Manhattan plot 389–391
- measurement requirement establishment 59–60
 - assay procedure 62
 - – accuracy 63–65
 - – linearity 67
 - – precision 62–65
 - – range 67–68
 - – specificity 65–67
 - identification 60–62
 - impurities 68–69
 - limit tests 69
 - – limit of detection (LOD) 69–70
 - – precision 70
 - – specificity 70
 - purpose 60
 - quantitative tests
 - – accuracy 70
 - – precision 71
 - – specificity and range 71
- measurement uncertainty 51, 182
 - estimation 53–55
 - meaning 51–52

- random variability sources 55
- reporting 52–53
- method capability index 78
- method design and understanding 191–192
 - analytical quality by design (AQbD) 217–220, 223–241
 - control strategy 239–240
 - design of experiments (DOE) 225–227
 - failure mode effect analysis (FMEA) 227–230
 - illustrative case study 231–234
 - method validation requirements 220–221
 - robustness 221–223
 - statistical analysis for robustness example 234
 - case study robustness investigations 241–243
 - basic and intrinsic parameters 243–245
 - computer-assisted robustness studies examples 245–287
 - development 194–205
 - optimization 203, 206–217
 - selection 192–194
 - system suitability tests (SSTs) 287–288
 - chromatographic parameters 288–293
 - design 294
 - non-chromatographic system parameters 293–294
- method operable design region (MODR) 209, 212–215, 219, 237
- method performance characteristics 73–74
 - accuracy and range 119–121, 137
 - acceptance criteria (ATP requirements) 132–135
 - accuracy and precision joint evaluation 136
 - drug product 126–127
 - drug substance 122–126
 - integration mode accuracy 130–131
 - response factors 131–132
 - spiked impurities recovery 129–130
 - detection and quantitation limit
 - approached based on blank 167
 - comparison of approaches 175–176
 - DL/QL determination from linearity 167–174
 - pharmaceutical impurity determination requirements 164–167
 - precision-based approaches 174–175
 - linearity 145–147, 163–164
 - calibration models 162
 - nonlinear and regression techniques 162–163
 - unweighted linear regression 147–160
 - weighted linear regression 160–161
 - precision 74
 - acceptance criteria 95–107
 - benchmarks 107–116
 - concentration dependency 93–95
 - levels 84–89
 - normal distribution and parameters 74–84
 - sources 116–118
 - and variance calculation 89–93
 - specificity 137–140, 145
 - chromatographic resolution 140–141
 - demonstration by accuracy 140
 - peak purity (co-elution) 141–145
- method performance qualification 303–305
 - analytical procedures transfer 348–349
 - comparative testing 355–371
 - coordination 350, 352
 - experimental studies design and acceptance criteria 353, 355
 - familiarization and training 353
 - regulatory and international guidance 349–350
 - result evaluation and transfer report 355
 - strategy 352–353
 - compendial/pharmacopeia test procedures implementation 348
 - background 337
 - challenges and need for verification 338–339
 - current approach to verification of procedures 339–340
 - current verification process and lifecycle approach integration 340
 - generation and publishing of methods 336–337
 - implementation using lifecycle approach 341–346
 - performance qualification 346–347
 - use of procedures in laboratory for first time 339
 - HPLC method qualification for identity, assay, and degradation products case study 308–310
 - accuracy 318–320
 - experimental 310
 - linearity 314–318
 - precision 320–321
 - qualification summary 310, 313–314
 - quantitation limit 321, 323
 - range 323–324
 - specificity 314
 - precision study example 305–307

- method performance qualification (*contd.*)
 - pressurized metered dose inhaler delivered dose uniformity procedure design and qualification
 - analytical control strategy summary 336–337
 - analytical procedures 324–325
 - design to meet ATP 326–334
 - human and environmental factors 325
 - performance characteristics 334–335
 - qualification 335–336
 - testing for inhalation products 325–326
 - method qualification 9
 - mixture-related factors, in robustness studies 266–267
 - mobile phase proportioning 30
 - MODDE software package 267, 270, 271, 275, 280, 281, 286, 287
 - model independent tests 157–158
 - multiple linear regression (MLR) 262
- n**
- noise and drift measurement 30–32
 - non-chromatographic system parameters 293
 - normal distribution curve 45
- o**
- observed bias 133
 - omeprazole 61
 - one-factor-a-time (OFAT) approach 245
 - operationally defined procedure. *See* empirical procedure
 - operational qualification (OQ) 15, 26
 - comparison with SST data 32–33
 - revised parameter list development 27–29
 - out-of expectation (OOE) 385, 394, 399–405
 - out-of-specification (OOS) 386, 391, 393, 405
- p**
- percentage recovery calculation 127–128
 - performance-based approach 61
 - performance qualification (PQ) 15, 26–27
 - comparison with SST data 32–33
 - general procedures 34–36
 - revised list for HPLC instrument qualification 28
 - Plackett-Burman design 226–228, 260, 267–270, 279, 286
 - precision 62–63, 119, 178, 335
 - acceptance criteria
 - acceptable precision for assay 101–105
 - acceptable precision for impurities and minor components 105–107
 - calibration format optimization 97–101
 - benchmarks 107–108
 - intermediate precision and reproducibility 115–116
 - repeatability 108, 112–115
 - system precision 108
 - concentration dependency 93–95
 - intermediate precision and reproducibility 86, 88–89
 - levels 84–89
 - limit tests 70
 - normal distribution and parameters 74–84
 - quantitative tests 71
 - relationship with accuracy 64–65
 - repeatability 86
 - reportable result 95–97
 - sources 116–117
 - stability studies 117–118
 - system and instrument precision 85–86
 - variance calculation 89–93
 - from linear regression 92–93
 - prediction interval 150–151
 - prediction profiler 235–236
 - pressurized metered dose inhaler delivered dose uniformity procedure design and qualification
 - analytical control strategy summary 336–337
 - analytical procedures 324–325
 - design to meet ATP 326–334
 - human and environmental factors 325
 - performance characteristics 334–335
 - qualification 335–336
 - testing for inhalation products 325–326
 - probability approach 64, 102–105
 - procedure acceptance criteria 61
 - procedure performance acceptance criteria (PPAC) 51, 59–64, 69
 - procedure performance measures (PPMs) 51, 59–61, 63, 65, 68
 - proportional model 158
 - pure error 271, 274
- q**
- qualification 19, 25
 - design (DQ) 14
 - installation (IQ) 14, 26
 - method 9
 - operational (OQ) 15, 26
 - performance (PQ) 15, 26–28, 32–36
 - qualified equipment 8
 - qualitative factors, in robustness studies 266
 - quality analytical profile (QAP) 223

- quality by design (QbD) 2–3, 9, 41–42, 194, 197, 214
 - method terminology 220
- quality risk management (QRM) 11
- quality target method profile (QTMP) 223
- Quality Target Product Profile 5–6
- quantitation limit 164, 176–177, 181, 321, 323
 - approached based on blank 167
 - comparison of approaches 175–176
 - DL/QL determination from linearity 167–169
 - – approach based on German Standard DIN 172–173
 - – regression line 95% prediction interval 171–174
 - – relative uncertainty 173–174
 - – standard deviation of response 169–171
 - pharmaceutical impurity determination requirements 164–165
 - – general quantitation limit 166–167
 - – intermediate quantitation limit 166
 - precision-based approaches 174–175
- quantitative factors, in robustness studies 265–266
- quantitative tests
 - accuracy 70
 - precision 71
 - specificity and range 71
- r**
- range 180, 323–324. *See also* under accuracy
 - assay procedure 67–68
 - quantitative tests 71
- rechromatography 141–142
- recording limit 172
- recovery 120, 122, 135, 319–320, 324
 - dose 333
 - function 128
 - impurities 129–130
 - percent 120, 126–128
- regression
 - linear 92–93
 - multiple (MLR) 262
 - unweighted 147–160
 - weighted 148, 160–161
- relative standard deviation (RSD) 7, 32–33, 65, 68–69, 75, 89–90, 94, 108, 135, 291, 292, 356, 363. *See also* precision
- repeatability 62, 86, 108, 112–115, 179, 292, 321
- repeated median estimator 163
- reportable result 6–8, 41–44, 95–97, 179–180, 228, 293, 303–305, 308, 324, 345–347
- reproducibility 63, 115–116, 179, 207–275
- residuals 151–152
- residual standard deviation 154–155, 170
- response factor 153
- reversed phase chromatography 137–138, 196, 199
- reversed-phase high-performance liquid chromatography (RP-HPLC) 198, 201
- risk assessment model 23
- risk priority number (RPN) 229–230
- robust parameter 84
- robustness investigations case study 242–243
 - basic and intrinsic parameters 243–245
 - computer-assisted robustness studies examples 245
 - – testing based on chromatography modeling software 246–258
 - – testing based on experimental design 258, 261–287
- root mean square error (RMSE) 234
- s**
- sensitivities 152–153
- shaking profile experiments 329–330
- signal-to-noise ratio 290–291
 - measurement 29
- significance tests 84, 122–124, 156
- solvent delivery system 29–30
- specification
 - limit 46, 82, 97, 101, 105, 119, 166, 309, 310
 - out-of 385, 391, 393, 405
 - performance-based 59
 - zone 42, 47–48
- specificity 60, 65, 137–140, 145, 181, 334
 - assay procedure 65–67
 - chromatographic procedures 65–66
 - chromatographic resolution 140–141
 - demonstration by accuracy 140
 - limit tests 70
 - non-chromatographic procedures 66–67
 - peak purity (co-elution) 141–145
 - quantitative tests 71
- spiking 126
- standard addition 128–129, 162
- standard deviation 102
 - calculation 89
 - confidence intervals 82
 - distribution 77
 - of intercept 170–171
 - normally distributed datasets 78–80

- standard deviation (*contd.*)
 - reporting 80–81
 - uncertainty 80, 83
 - standard error 81, 82
 - of prediction 129
 - statistical evaluations 158
 - statistical outlier tests, for out-of expectation results 399–405
 - studentized residuals 151
 - student-t-factor 82, 102
 - supercritical fluid chromatography (SFC) 196
 - system precision 80, 83, 85–87, 93, 108, 179, 291–293, 320–321
 - for impurities 293
 - system repeatability 292
 - system suitability tests (SSTs) 26–27, 83, 108, 117, 182, 214, 304, 380
 - chromatographic system suitability parameters 288–290
 - – injection precision 291
 - – signal-to-noise ratio 290–291
 - – system precision for impurities 293
 - – test for required detectability 291
 - comparison with operational and performance qualification data 32–33
 - design 294–295
 - non-chromatographic system parameters 293–294
- t**
- target measurement uncertainty
 - analysis cost 49–50
 - calculation 45–47
 - target standard deviation (TSD) 107
 - thermostating precision 29
 - tolerance/prediction interval approach 102
 - top-down approach precision 74
- u**
- United States Pharmacopeia (USP) General Chapter <1058> 12, 14
 - AIQ
 - – roles and responsibilities 17–18
 - – terminology clarification 19
 - analytical apparatus, instruments, and systems 19–20
 - analytical instrument qualification life cycle 14–15
 - data quality triangle 14
 - enhanced data quality triangle 20
 - increased granularity 18–19
 - instrument groups mapping to GAMP software categories 20
 - risk-based classification of apparatus, instruments, and systems 15–17
 - software validation 18
 - unweighted linear regression 147–160
 - user requirement specifications (URS) 26
- v**
- validation 19, 25, 59
 - analytical. *See* analytical validation
 - characteristics 2, 138
 - definition 59
 - during drug development 60–61, 126, 129
 - life-cycle 5, 8
 - of linearity 147
 - method 4, 220–221
 - pharmacopoeial methods 338
 - process 13, 378
 - protocol 140
 - simultaneous 137
 - software 18, 310
 - study 121
 - variance of injection 86
- w**
- wavelength accuracy 30
 - weighted regression 148
- z**
- z-scores 399–400

